尼洛替尼对比伊马替尼并在伊马替尼治疗无最佳反应时早期转换至尼洛替尼以获得初诊慢性髓性白血病患者无治疗缓解:首个共同主要终点分析
SUSTRENIM研究将448例初诊慢性期慢性髓性白血病患者按1:1随机分配至尼洛替尼组或伊马替尼组(伊马替尼组无最佳反应时早期转换至尼洛替尼),中位随访45.9个月。24个月随访时,尼洛替尼组达到MR4.5的比例显著高于伊马替尼组(65例 vs 42例,p=0.02),提示尽管伊马替尼组早期转换,尼洛替尼诱导深度分子学缓解更有效。
要点
- 448例初诊慢性期CML患者随机1:1接受尼洛替尼或伊马替尼(无最佳反应时转换至尼洛替尼)。
- 伊马替尼组220例中82例(37.2%)未达ELN最佳反应标准而转换至尼洛替尼。
- 24个月时尼洛替尼组达MR4.5者65例,伊马替尼组42例(p=0.02)。
核心结论
- 尽管伊马替尼随机组患者早期转换至尼洛替尼,尼洛替尼治疗在诱导深度分子学缓解方面仍比伊马替尼更有效。
研究设计与样本
- SUSTRENIM研究为随机对照研究,将初诊慢性期慢性髓性白血病患者按1:1随机分配至尼洛替尼组或伊马替尼组(伊马替尼组无最佳反应时转换至尼洛替尼)。
- 共纳入448例患者,尼洛替尼组228例,伊马替尼组220例,中位随访45.9个月。
主要发现
- 伊马替尼组220例中82例(37.2%)未满足ELN最佳治疗反应标准而转换至尼洛替尼。
- 24个月随访时,448例中107例达到MR4.5,尼洛替尼组65例 vs 伊马替尼组42例(p=0.02),尼洛替尼组频率显著更高。
关键数值与推荐
- 24个月随访时尼洛替尼组达MR4.5者65例,伊马替尼组42例(p=0.02)。
- 伊马替尼组220例中82例(37.2%)因未达ELN最佳反应标准而转换至尼洛替尼。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment-free remission is one of the most important goals of CML treatment but so far, the best treatment to reach this aim is still undefined, even though it is widely accepted that a sustained DMR is the prerequisite to discontinue TKI. Here we report on the depth of the molecular response, the first co-primary end point of the SUSTRENIM study, in a cohort of newly diagnosed CP-CML patients randomized 1:1 to be treated with nilotinib or with imatinib followed by switching to nilotinib in absence of optimal response. Of the 448 enrolled patients, 228 and 220 were randomized to the nilotinib (NIL) and imatinib (IM) arms, respectively, and followed for a median of 45.9 months. Eighty-two (37.2%) of the 220 patients on the IMarm did not fulfill the ELN criteria for optimal response of treatment and switched to nilotinib therapy. At the 24 months of follow-up, 107 of the 448 patients reached an MR4.5 response with a significantly higher frequency within the patients on the nilotinib arm (65 vs 42; p = 0.02). The analysis of the first primary endpoint indicates that, despite the early switch in the IM-randomized patients, NIL therapy is more effective to induce DMR.
引用
- Castagnetti F, Breccia M, Abruzzese E, et al. Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint. Leukemia. 2025. PMID: 41254114. doi:10.1038/s41375-025-02796-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。